Patent intelligence · US
US 10208089
Modulation of complement activity
Modulation of complement activity
Patent details — US 10208089
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 19, 2019
- Expiration
- Feb 14, 2039
- Applicant
- RA PHARMACEUTICALS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K47/64, A61K47/645
Quick answer
US 10208089 (Modulation of complement activity) is held by RA PHARMACEUTICALS, INC.. Status: granted. Granted Feb 19, 2019. Expires Feb 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K47/64, A61K47/645, A61P, A61P13/00
More from RA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10208089?
US 10208089 (Modulation of complement activity) is held by RA PHARMACEUTICALS, INC.. Status: granted. Granted Feb 19, 2019. Expires Feb 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10208089?
RA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10208089 expire?
Our index shows an expiration date of Feb 14, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.